Corneal Transplant Market Size, Share, Growth Analysis, By Indications, By Type, By End-user, By Region - Industry Forecast 2024-2031

Corneal Transplant Market size was valued at USD 455.8 million in 2022 and is poised to grow from USD 489.99 million in 2023 to USD 873.88 million by 2031, growing at a CAGR of 7.5% in the forecast period (2024-2031).

According to a report from the National Institutes of Health (NIH), approximately 10-15% of patients diagnosed with keratoconus may require a corneal implant procedure as part of their treatment regimen. This highlights the critical role of corneal implants in managing and mitigating the effects of keratoconus, a condition that affects a significant portion of the population. Additionally, corneal blindness represents a significant global health issue, ranking as the third-leading cause of blindness after glaucoma and cataracts, impacting an estimated 10 million individuals worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Corneal Transplant market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Corneal Transplant Market Segmental Analysis

The corneal transplant market is segmented based on indication, type, end user, and region. Based on indications, the market is segmented into fungal corneal ulcer, bullous keratopathy, keratoconus, keratitis, corneal stromal dystrophies, and others. Based on type, the market is segmented into penetrating keratoplasty, endothelial keratoplasty, descemet stripping automated endothelial keratoplasty, corneal graft, corneal limbal stem cell transplant, and others. Based on end-user, the market is segmented into hospitals, eye clinics, and others. By region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Drivers of the Corneal Transplant Market

The corneal transplant market is experiencing substantial growth, driven primarily by the rising prevalence of conditions such as keratoconus, Fuchs dystrophy, keratitis, and cataracts, which often necessitate corneal transplantation as a crucial medical intervention. Data from the Eye Research Foundation in the US indicates a significant burden, with approximately 100,000 individuals affected by these conditions, including an estimated 50 to 200 individuals grappling with complex corneal diseases like keratoconus. This prevalence underscores the increasing demand for corneal implants, highlighting their essential role in treating various eye disorders.

Restraints in the Corneal Transplant Market

The corneal transplant market encounters notable obstacles due to the substantial expenses involved in treatment and a scarcity of donor tissue, which are significant constraints on its expansion. The costs associated with corneal transplantation, including pre-operative evaluations, surgical procedures, and post-operative management, impose a considerable financial burden on both patients and healthcare systems. This high cost can restrict accessibility, particularly in areas with limited healthcare infrastructure.

Market Trends of the Corneal Transplant Market

The remarkable expansion seen in the corneal transplant market stems from various factors contributing to heightened demand for these advanced treatments. One prevalent condition driving this growth is late-onset Fuchs endothelial corneal dystrophy, which predominantly affects individuals aged 40 and older, as reported in a March 2020 article in the journal Progress in Retina and Eye Research.